Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
Mohammed Al Amine El Farissi, Youness Dehneh, Amine Kada, Mohamed Dahamou, Mohamed Khoulali, Noureddine Oulali, Faycal Moufid
Anaplastic large cell lymphoma (ALCL) is a rare variety of non-Hodgkin lymphoma that primarily affects children and young adults and is caused by the fusion of the nucleophosmin 1 and ALK genes, which turns on several signalling pathways. Despite the fact that ALCL frequently affects lymph nodes and extranodal sites, involvement of the central nervous system (CNS) is quite uncommon, with symptoms like pain and fever. The spinal localization may result in neurological impairments. T1WI hypointense lesions with T2WI hyperintensity can be observed on MR images, while bone sequestra can be seen in CT scans...
January 2024: Radiology Case Reports
#22
Yasuhiro Tanaka, Takashi Kido, Noriho Sakamoto, Atsuko Hara, Takeharu Kato, Ritsuko Miyashita, Mutsumi Ozasa, Takatomo Tokito, Daisuke Okuno, Kazuaki Takeda, Hirokazu Yura, Shinnosuke Takemoto, Takahiro Takazono, Hiroshi Ishimoto, Yasushi Obase, Yuji Ishimatsu, Yasushi Miyazaki, Hiroshi Mukae
The diagnosis of pulmonary lymphoma using small tissue samples is difficult and often requires surgical procedures; thus, a less invasive sampling method is desirable. Moreover, pulmonary involvement in adult T-cell lymphoma (ATL) is often difficult to diagnose, especially in cases without characteristic flower cells. Here, we present the case of a 78-year-old man, in whom pathological examination of the transbronchial lung biopsy (TBLB) specimen did not reveal malignant findings; therefore, transbronchial lung cryobiopsy (TBLC) in combination with endobronchial ultrasonography (EBUS) was used to diagnose ATL based on the pathological findings...
November 16, 2023: Medicina
#23
Kenjiro Nagai, Syo Nagai, Yuji Okubo, Keisuke Teshigawara
BACKGROUND: The prognosis of patients with advanced diffuse large B-cell lymphoma (DLBCL) is poor, with a 5-year survival rate of approximately 50%. The mainstay of treatment is multidrug combination chemotherapy, which has been associated with serious side effects. Amplified natural killer (ANK) cell therapy amplifies and activates natural killer (NK) cells to attack only malignant tumors. As ANK cells attack programmed death ligand 1 (PD-L1)-positive tumor cells, ANK therapy is considered effective against adult T-cell lymphoma and malignant lymphoma...
October 26, 2023: World Journal of Clinical Cases
#24
JOURNAL ARTICLE
Ana Benzaquén, Estela Giménez, Gloria Iacoboni, Manuel Guerreiro, Rafael Hernani, Eliseo Albert, Cecilia Carpio, Aitana Balaguer, Ariadna Pérez, Carlos S de la Asunción, Mario Andrés Sánchez-Salinas, Pedro Chorão, José Luis Piñana, Francisco Beas, Juan Montoro, Juan Carlos Hernández-Boluda, Ana Facal, Blanca Ferrer, Marta Villalba, Paula Amat, María Dolores Goméz, Diana Campos, María José Terol, Jaime Sanz, Pere Barba, David Navarro, Carlos Solano
Torque Teno Virus (TTV) is a single-stranded circular DNA virus which has been identified as a surrogate marker of immune competence in transplantation. In this study we investigated the dynamics of plasma TTV DNAemia in 79 adult patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory large B-cell lymphoma, also evaluating the impact of TTV on immunotoxicities, response and survival outcomes. After lymphodepleting therapy, TTV DNA load was found to decrease slightly until reaching nadir around day 10, after which it increased steadily until reaching maximum load around day 90...
January 2024: Bone Marrow Transplantation
#25
JOURNAL ARTICLE
Alexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna M Voutsinas, Qian Vicky Wu, Cecilia C S Yeung, Nicolas Gazeau, Barbara S Pender, Delaney R Kirchmeier, Aiko Torkelson, Abigail Chutnik, Ryan D Cassaday, Aude G Chapuis, Damian J Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G Till, Stanley R Riddell, David G Maloney, Cameron J Turtle
Over half of the patients treated with CD19-targeted chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy for large B-cell lymphoma (LBCL) do not achieve durable remission, which may be due in part to PD-1/PD-L1-associated CAR-T cell dysfunction. We report data from a phase 1 clinical trial, in which adults with LBCL were treated with autologous CD19 CAR-T cells (JCAR014) combined with escalating doses of the anti-PD-L1 monoclonal antibody, durvalumab, starting either before or after CAR-T cell infusion...
October 30, 2023: Blood Advances
#26
Nan Zhang, Xiao-Juan Miao, Yan-Rong Shuai, Hao Yao, Fang-Yi Fan, Yi-Lan Liu
Acute myeloid leukemia (AML) is a large class of heterogeneous hematological malignancies with the highest incidence rate in acute leukemia. Its pathogenesis is still unclear, which may be related to genetics. According to the latest AML NCCN guidelines, genes involved in AML family genetic changes include RUNX1, ANKRD26, CEBPA. Finding new genes related to AML genetics is of great significance for predicting the prognosis of patients, developing targeted drugs, and selecting transplant donors. Here, we report a case of adult female AML patient whose three relatives suffered from hematological malignancies, including Waldenstrom macroglobulinemia, NK/T-cell lymphoma, and angioimmunoblastic T-cell lymphoma...
2023: Case Reports in Oncology
#27
JOURNAL ARTICLE
Tatsu Shimoyama
Recent advances with chimeric antigen receptor T-cell (CAR-T) therapy are changing the current landscape of poor-prognosis relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Pivotal trials leading to the FDA approval of three CD19 CAR-T cells, namely, Yescarta® , Kymriah® , and Breyanzi® , demonstrated complete response rates of 40-60%, with a significant subset of patients achieving long-term disease remission, and real-world studies confirm these data. In Japan, CAR-T therapy was approved for R/R DLBCL in 2019 and for R/R follicular lymphoma in 2022...
2023: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
#28
JOURNAL ARTICLE
James N Gerson, Elizabeth Handorf, Diego Villa, Alina S Gerrie, Parv Chapani, Shaoying Li, L Jeffrey Medeiros, Michael L Wang, Jonathan Cohen, Michael C Churnetski, Brian T Hill, Yazeed Sawalha, Francisco J Hernandez-Ilizaliturri, Shalin K Kothari, Julie M Vose, Martin A Bast, Timothy S Fenske, Swapna Narayana Rao Gari, Kami J Maddocks, David A Bond, Veronika Bachanova, Bhaskar Kolla, Julio C Chavez, Bijal D Shah, Frederick Lansigan, Timothy F Burns, Alexandra Donovan, Nina D Wagner-Johnston, Marcus Raymond Messmer, Amitkumar Mehta, Jennifer Anderson, Nishitha Reddy, Alexandra Kovach, Daniel J Landsburg, Martha J Glenn, David J Inwards, Kay Ristow, Reem Karmali, Jason Kaplan, Paolo F Caimi, Saurabh A Rajguru, Andrew M Evens, Andreas K Klein, Elvira Umyarova, Bhargavi Pulluri, Jennifer Effie Amengual, Jenniver K Lue, Catherine Diefenbach, Richard I Fisher, Stefan K Barta
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicates that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000-2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of 1029 MCL patients studied, a total of 207 neoplasms were blastoid or pleomorphic variant...
October 24, 2023: Blood Advances
#29
Nkechi Arinze, Nivin Omar, Amany Keruakous, Ravindra Kolhe, Natasha Savage
Mantle cell lymphoma (MCL) is an intermediate-grade B-cell lymphoma, representing 2.8% of all non-Hodgkin lymphomas in the US. It is associated with t(11;14)(q13; q23), which leads to the overexpression of cyclin D1, consequently promoting cell proliferation. MCL usually expresses CD19, CD20, CD43, surface immunoglobulins, FMC7, BCL2, cyclin D1, CD5, and SOX11. Herein is a case of a 67-year-old male, referred to our facility with shortness of breath, anemia (hemoglobin of 5.3 g/dL), thrombocytopenia (12 × 109 /L), and leukocytosis (283 × 109 /L)...
October 13, 2023: Hematology Reports
#30
JOURNAL ARTICLE
Zhi-Gang Sun, Cheng-Jie Yao, Inam Ullah, Zhu Hailiang
Leukemia and lymphoma are the most common blood cancers, which pose a critical threat to the health of adults and children. The total incidence and mortality rates of both are approximately 6% globally. Compared with the expensive cost of CAR T cell therapy, natural products from animals, plants and microorganisms have the characteristics of wide-range sources and costeffectiveness in the treatment of cancer. Moreover, the drug resistance that emerged in leukemia and lymphoma treatments shows an urgent need for new drugs...
October 6, 2023: Mini Reviews in Medicinal Chemistry
#31
REVIEW
Ilias Pessach, Arnon Nagler
Chimeric antigen receptor (CAR) T-cell therapy is an effective, individualized immunotherapy, and novel treatment for hematologic malignancies. Six commercial CAR-T cell products are currently approved for lymphatic malignancies and multiple myeloma. In addition, an increasing number of clinical centres produce CAR-T cells on-site, which enable the administration of CAR-T cells on site. The CAR-T cell products are either fresh or cryopreserved. Manufacturing CAR-T cells is a complicated process that begins with leukapheresis to obtain T cells from the patient's peripheral blood...
December 2023: Transfusion and Apheresis Science
#32
JOURNAL ARTICLE
Mitul B Modi, Alexandra Kiszluk, Jiani N Chai, Ukuemi Edema, Maxwell Y Ma, R Alejandro Sica, Yanhua Wang, Yang Shi
OBJECTIVES: Adult T-cell leukemia/lymphoma (ATLL) is a rare aggressive T-cell leukemia/lymphoma associated with human T lymphotropic virus type 1 infection. The patients might present with skin rash before, at, or after the diagnosis. The dermatopathologic finding might be diagnostically very challenging. METHODS: We retrospectively identified 110 patients with ATLL at a single institution in a 19-year period, with 19 patients having skin biopsies. Clinical, dermatopathologic, immunophenotypic, and molecular findings were studied...
February 1, 2024: American Journal of Clinical Pathology
#33
JOURNAL ARTICLE
K A Kumar, R Ravella, P Ramakrishnan Geethakumari, F Awan, T A Aguilera, X Li, O K Öz, A Kandathil, W Chen, F Fuda, C Ahn, P Iyengar, N B Desai, R D Timmerman
PURPOSE/OBJECTIVE(S): Inpatients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) treated with CD19-directed CAR-T, only ∼40% achieve complete response (CR) by day 30 PET/CT evaluation. Of those who do not, the large majority (∼70%) ultimately fail, providing an ideal target for early therapeutic intervention to 're-prime' CAR-T. Preclinical and early clinical studies suggest potential synergy and immune augmentation when combining RT with CAR-T. Here we report the phase I results of a prospective phase I/II clinical trial hypothesizing that early salvage focal RT to poor responding sites of disease after CAR-T in R/R NHL patients is safe (phase I) and will improve conversion to CR by day 90 post-CAR-T PET/CT from 29% (historical control) to 58% (phase II)...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
#34
JOURNAL ARTICLE
Maria Trottmann, Eva Blozik, Marcel Hilbig, Daniel LoVerdi, Marcello Pedruzzi, Tina Scherer, Martina Weiss, Mark Pletscher, Niklaus Meier
AIM OF THE STUDY: Newly approved therapies with high and uncertain budget impact pose challenges to public health care systems worldwide. One recent example is chimeric antigen receptor T cell (CAR-T) therapies for adults with large B-cell lymphoma (LBCL). This study's primary objective is to examine the expenditures of Swiss public payers before, during, and after CAR-T cell therapy in patients with LBCL aged ≥30 years. Its secondary objective is to analyse 24-month survival rates...
September 29, 2023: Swiss Medical Weekly
#35
JOURNAL ARTICLE
Aaron Trando, Anna Ter-Zakarian, Phillip Yeung, Aaron M Goodman, Ayad Hamdan, Michael Hurley, Ah-Reum Jeong, Dimitrios Tzachanis
Chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We describe the real-world baseline characteristics, efficacy, safety, and post-relapse outcomes of adult patients with R/R LBCL who received CAR T-cell therapy at the University of California San Diego. A total of 66 patients with LBCL were treated with tisagenlecleucel or axicabtagene ciloleucel. The median age was 59.5, and 21% were over 70 years old. Additionally, 20% of the patients had an Eastern Cooperative Oncology Group (ECOG) performance score of ≥2...
September 21, 2023: Cancers
#36
JOURNAL ARTICLE
Marie Ohbiki, Yuri Ito, Yoshihiro Inamoto, Koichi Miyamura, Naoyuki Uchida, Takahiro Fukuda, Hiroki Fujiwara, Tetsuya Nishida, Masayasu Hayashi, Masatsugu Tanaka, Toshiro Kawakita, Kazuhiro Ikegame, Yuta Katayama, Takahide Ara, Tatsuo Ichinohe, Hitoshi Kiyoi, Keitaro Matsuo, Yoshiko Atsuta
BACKGROUND: Allogeneic (allo-) hematopoietic cell transplantation (HCT) has evolved as a curative therapy for hematologic malignancies and diseases, with practice changes over the past two decades. OBJECTIVE: This study aimed to evaluate the change in 5-year net survival (NS) of allo-HCT recipients in a population-based cohort over the past two decades, which allows the estimation of a more HCT-specific long-term survival rate by considering background mortality changes...
September 20, 2023: Transplantation and cellular therapy
#37
JOURNAL ARTICLE
Manisha Gadgeel, Ishaq Al Kooheji, Batool Al-Qanber, Steven Buck, Süreyya Savaşan
T-large granular lymphocytes (T-LGL) characterized by dim CD5 staining, although not completely understood, have unique roles in the immune system. Expansion of peripheral blood (PB) clonal T-LGL populations is associated with various entities in adults. We have previously demonstrated clonal T-LGL proliferations in pediatric immune dysregulation/inflammatory/proliferative conditions. However, T-LGL populations have not been studied in broader spectrum pathologies. In this study we evaluated sizes and correlates of T-LGL populations in the pediatric and young adult populations with various disease states...
September 21, 2023: Annals of Hematology
#38
JOURNAL ARTICLE
Anne Sofie Ledgaard Loftager, Anne Danø, Oskar Eklund, Sachin Vadgama, Viktor Hedlof Kanje, Emma Munk
AIM: Our study aimed to evaluate the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel), compared to standard of care (SOC) in Sweden for second-line (2L) treatment of adult transplant-intended diffuse large B-cell lymphoma (DLBCL) patients who relapse within 12 months from completion of, or are refractory to (early r/r), first-line (1L) chemoimmunotherapy. METHODS: Cost-effectiveness was assessed using a three-state partitioned survival model...
September 19, 2023: Journal of Medical Economics
#39
REVIEW
Michael T Czapka, Peter A Riedell, Jennifer C Pisano
BACKGROUND: CAR T-cell therapy, where a patient's own T cells are re-engineered to express a receptor to a target of interest, is becoming an increasingly utilized cancer-directed therapy. There are significant toxicities that contribute to a novel state of immunocompromise, leading to new patterns of infectious complications that require further detailed study. METHODS: We created a single-center cohort of adult recipients of CD19-directed CAR T-cell therapy and assessed infectious outcomes, supportive care received, toxicities, and markers of immune function up to 2 years following CAR T-cell therapy...
September 11, 2023: Transplant Infectious Disease: An Official Journal of the Transplantation Society
#40
JOURNAL ARTICLE
Carmen de Mendoza, Ariadna Rando, Elisenda Miró, María José Pena, Iciar Rodríguez-Avial, Diego Ortega, Alejandro González-Praetorius, Gabriel Reina, Ilduara Pintos, María José Pozuelo, Vicente Soriano
BACKGROUND: HTLV-1 infection is a neglected disease, despite producing neurological and lymphoproliferative severe illnesses and affect over 10 million people worldwide. Roughly 5% of HTLV-1 carriers develop Adult T-cell leukemia/lymphoma (ATLL), one of the most aggressive hematological malignancies. METHODS: A national HTLV-1 register exists since 1989 in Spain, a non-endemic country with a large migrant flow from Latin America and Equatorial Africa, where HTLV-1 is endemic...
August 28, 2023: Journal of Clinical Virology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
